Skip to main content

Natalizumab News

Adverse Outcomes Seen With MS Disease-Modifying Drugs in Pregnancy

THURSDAY, Jan. 2, 2025 – Disease-modifying therapy (DMT) use for multiple sclerosis (MS) in pregnancy is associated with certain adverse outcomes, including small for gestational age, according to a...

FDA Approves Tyruko (natalizumab-sztn), a Biosimilar to Tysabri

August 24, 2023 – The U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing...

FDA Medwatch Alert: Tysabri (natalizumab): Drug Safety Communication - New Risk Factor for Progressive Multifocal Leukoencephalopathy (PML)

ISSUE: FDA notified healthcare profesisonals that testing positive for anti-JC virus (JCV) antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML). PML is...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Multiple Sclerosis, Crohn's Disease - Maintenance

Natalizumab patient information at Drugs.com